Cure My Disease

Don't miss your cure!

 Log in / Sign up

New triple drug combo could beat malaria resistance

NCT ID NCT05951595

Recruiting now ⭐️ CURE ⭐️ Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new triple-drug combination (artemether-lumefantrine-amodiaquine) against standard two-drug treatments for uncomplicated malaria. About 1680 people with malaria will receive one of the treatments and be monitored for 42 days. The goal is to see if the triple therapy works as well or better, especially against drug-resistant malaria.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Plasmodium falciparum malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ruhuha Health Centre

    RECRUITING

    Ruhuha, Eastern Province, Rwanda

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••